Compare Aegon Ltd. (AEG) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aegon Ltd. vs DexCom, Inc. — how do they compare? Aegon Ltd. trades at $9.43 (market cap $14.01B), while DexCom, Inc. trades at $89.32 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 2.4× Aegon Ltd.'s market cap, and Aegon Ltd. pays a 4.94% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| AEG | DXCM | |
|---|---|---|
Market Cap | $14.01B | $33.79B |
Sector | Financials | Health |
52-Week High | $9.53 | $89.53 |
52-Week Low | $6.79 | $54.84 |
Enterprise Value | $15.16B | $33.24B |
Dividend Yield | 4.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $9.45, down 0.84% today, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company maintains a P/E of 13.54 and P/S of 0.57, indicating potential undervaluation, while a strategic shift to U.S. focus and a $0.25 dividend highlight corporate stability.
The outlook is cautiously optimistic, supported by deleveraging trends and revenue growth projections to $26.9B in 2025. Risks include volatile cash flows and competitive pressures, but analyst consensus leans hold with 50% rating, suggesting steady performance amid transformation efforts.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
